The case for cost‐effectively treating cryoglobulinemic vasculitis with interferon‐free anti–hepatitis C virus therapy

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 975-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low Prevalence of Anti-Hepatitis C Virus Antibodies in Mexico: A Systematic Review

By  

Intervirology, Vol. 50, Iss. 1, 2006-11 ,pp. : 1-8

Karger

Access to resources Recommend Favorite

Optimal duration of pre‐liver transplantation anti‐hepatitis C virus treatment with direct‐acting agent sofosbuvir

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1776-1776

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing?

By  

Intervirology, Vol. 58, Iss. 5, 2015-0 ,pp. : 310-317

Karger

Access to resources Recommend Favorite

Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF‐κB‐ and MAPK‐ERK1/2‐mediated COX‐2 expression

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 18, 2015-09 ,pp. : 4481-4492

John Wiley & Sons Inc

Access to resources Recommend Favorite